Tmunity Signs an Exclusive Research Agreement with the University of California to Advance TCR Therapies for Pediatric Cancers

Tmunity Signs an Exclusive Research Agreement with the University of California to Advance TCR Therapies for Pediatric Cancers

Shots:

  • Tmunity & University of California enter into an exclusive research agreement for the improvement of TCR therapies for rare diseases including DIPG in pediatric patients. Tmunity will be responsible for development & commercialization of the H3.3K27M TCR therapy
  • The focus of the collaboration is to strengthen Tmunity’s portfolio by developing therapies for diffuse intrinsic pontine glioma (DIPG) targeting H3.3K27M i.e, K27M mutation in the H3.3 histone
  • Tmunity’s portfolio includes T cell therapy platforms, T cell receptors, regulatory T cells, gene transfer, allogeneic T cells and bionic T cells & CAR-T programs used for activating or suppressing immunity

Click here to read full press release/ article | Ref: Tmunity | Image: Pinterest